Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

. 2022 Oct 25 ; 99 (17) : e1926-e1944. [epub] 20220817

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu pozorovací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid35977837
E-zdroje Online Plný text
Odkazy

PubMed 35977837
PubMed Central PMC9620810
DOI 10.1212/wnl.0000000000201029
PII: WNL.0000000000201029
Knihovny.cz E-zdroje

BACKGROUND AND OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHODS: This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULTS: A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). DISCUSSION: The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod). CLASSIFICATION OF EVIDENCE: This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.

Zobrazit více v PubMed

Kalincik T, Kubala Havrdova E, Horakova D, et al. . Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458-468. PubMed

Warrender-Sparkes M, Spelman T, Izquierdo G, et al. , MSBase Study Group. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Mult Scler. 2016;22(4):520-532. PubMed

Hartung HP, Gonsette R, Konig N, et al. , Mitoxantrone in Multiple Sclerosis Study Group MIMS. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-2025. PubMed

Sorensen PS, Bertolotto A, Edan G, et al. . Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-152. PubMed

Berkovich R. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. Mult Scler Relat Disord. 2017;17:123-127. PubMed

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. PubMed PMC

Barry B, Erwin AA, Stevens J, Tornatore C. Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther. 2019;8(2):241-250. PubMed PMC

Kister I, Spelman T, Patti F, et al. . Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. J Neurol Sci. 2018;391:72-76. PubMed

Jokubaitis VG, Li V, Kalincik T, et al. , MSBase Study Group. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82(14):1204-1211. PubMed PMC

Bsteh G, Feige J, Ehling R, et al. . Discontinuation of disease-modifying therapies in multiple sclerosis–clinical outcome and prognostic factors. Mult Scler .2017;23(9):1241-1248. PubMed

O'Connor PW, Goodman A, Kappos L, et al. . Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858-1865. PubMed

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170-1177. PubMed

Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790-794. PubMed

Frau J, Sormani MP, Signori A, et al. , i-MuST study group. Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol. 2018;25(10):1270-1275. PubMed

Prosperini L, Annovazzi P, Capobianco M, et al. . Natalizumab discontinuation in patients with multiple sclerosis: profiling risk and benefits at therapeutic crossroads. Mult Scler. 2015;21(13):1713-1722. PubMed

FDA. FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod) [online]. Accessed November 10, 2020. fda.gov/drugs/drug-safety-and-availability/fda-warns-about-severe-worsening-multiple-sclerosis-after-stopping-medicine-gilenya-fingolimod.

Giovannoni G, Hawkes C, Waubant E, Lublin F. The “Field Hypothesis”: rebound activity after stopping disease-modifying therapies. Mult Scler Relat Disord. 2017;15:A1-A2. PubMed

Polman CH, Reingold SC, Banwell B, et al. . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. PubMed PMC

Polman CH, Reingold SC, Edan G, et al. . Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol. 2005;58(6):840-846. PubMed

Kunchok A, Malpas C, Nytrova P, et al. . Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2020;38:101868. PubMed

Stellmann JP, Krumbholz M, Friede T, et al. , NEMOS Neuromyelitis Optica Study Group. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88(8):639-647. PubMed PMC

Roos I, Leray E, Casey R, et al. . High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag. Mult Scler J. 2020;26:534-535.

Vukusic S, Casey R, Rollot F, et al. . Observatoire Francais de la Sclerose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France. Mult Scler. 2020;26(1):118-122. PubMed

Kalincik T, Butzkueven H. The MSBase registry: informing clinical practice. Mult Scler. 2019;25(14):1828-1834. PubMed

Kalincik T, Kuhle J, Pucci E, et al. , MSBase Scientific Leadership Group and MSBase Study Group. Data quality evaluation for observational multiple sclerosis registries. Mult Scler. 2017;23(5):647-655. PubMed

Schumacher GA, Beebe G, Kibler RF, et al. . Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552-568. PubMed

Kalincik T, Cutter G, Spelman T, et al. . Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(pt 11):3287-3298. PubMed

Kappos L, Wolinsky JS, Giovannoni G, et al. . Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132-1140. PubMed PMC

Butzkueven H, Chapman J, Cristiano E, et al. . MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):769-774. PubMed

Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664. PubMed PMC

Westreich D, Cole SR, Tien PC, et al. . Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol. 2010;171(6):691-700. PubMed PMC

Plavina T, Muralidharan KK, Kuesters G, et al. . Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89(15):1584-1593. PubMed PMC

Fox RJ, Cree BAC, De Seze J, et al. , RESTORE. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-1498. PubMed PMC

Papeix C, Vukusic S, Casey R, et al. , TYSEDMUS and OFSEP Group. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurology Neuroimmunol Neuroinflamm. 2016;3(6):e297. PubMed PMC

Malpas CB, Roos I, Sharmin S, et al. . Disease Reactivation Following Fingolimod Cessation (P667): European Committee for Treatment and Research in Multiple Sclerosis; 2019.

Sanchez P, Meca-Lallana V, Vivancos J. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases. Mult Scler Relat Disord. 2018;25:95-98. PubMed

Francis G, Kappos L, O'Connor P, et al. . Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471-480. PubMed

Le Page E, Leray E, Taurin G, et al. . Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79(1):52-56. PubMed

Jokubaitis VG, Spelman T, Kalincik T, et al. , MSBase Study Group. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016;80(1):89-100. PubMed

Kister I, Spelman T, Alroughani R, et al. , MSBase Study Group. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87(10):1133-1137. PubMed

Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(pt 3):595-605. PubMed

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616. PubMed

Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438. PubMed

Kalincik T, Butzkueven H. Observational data: understanding the real MS world. Mult Scler. 2016;22(13):1642-1648. PubMed

Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1:2055217315596994. PubMed PMC

Nagy S, Kuhle J, Derfuss T. Lymphocyte recovery after fingolimod discontinuation in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e874. PubMed PMC

Najít záznam

Citační ukazatele

Možnosti archivace